Showing 1321-1330 of 1484 results for "".
- RayOne Aspheric Fully Preloaded IOL Receives FDA Clearancehttps://modernod.com/news/rayone-aspheric-fully-preloaded-iol-receives-fda-clearance/2479618/Rayner announced that the FDA has cleared the RayOne Aspheric fully preloaded IOL injection system for use in the United States. The FDA granted regulatory clearance of the RayOne Aspheric Monofocal (RAO600C), a fully preloaded aberration-neutral IOL covering a power range of +8.0 D to +34
- Santen Launches Verkazia for Children and Adolescents with Severe Allergic Eye Conditionhttps://modernod.com/news/santen-launches-verkazia-for-children-and-adolescents-with-severe-allergic-eye-condition/2479744/Santen UK announced the launch of Verkazia eye drops emulsion containing 0.1% (1mg/ml) ciclosporin for the treatment of the rare disease severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. Verkazia, which has been granted orphan drug status, provides a much-n
- IDx and Topcon Sign Exclusive AI Platform Agreement For the U.S. Markethttps://modernod.com/news/idx-and-topcon-sign-exclusive-ai-platform-agreement-for-the-u-s-market/2479766/AI diagnostics company IDx and Topcon have signed an exclusivity agreement that will allow the companies to scale delivery of AI-based diagnostic solutions in the United States. Terms of the deal were not disclosed. The agreement grants exclusive rights to IDx in the US as the only
- Chinese Regulators Clear Takeda’s $62-Billion Takeover of Shirehttps://modernod.com/news/chinese-regulators-clear-takedas-62-billion-takeover-of-shire/2479882/Takeda said that China’s State Administration for Market Regulation has granted unconditional approval of its proposed $62-billion purchase of Shire. The Japanese drugmaker expects to complete the transaction in the first half of next year. China’s regulatory clearance “
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Diseasehttps://modernod.com/news/lin-bioscience-receives-ema-orphan-drug-status-for-lbs-008-for-the-treatment-of-stargardt-disease/2480056/Lin BioScience announced that the European Medicines Agency has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is currently an untreatable inherited condition that causes permanent vision loss in children
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Johnson & Johnson Marks 100,000 US Implants of Tecnis Odyssey IOL; Showcases Innovations at AAO 2025https://modernod.com/news/johnson-johnson-marks-100000-us-implants-of-tecnis-odyssey-iol-and-showcases-innovations-at-aao-2025/2484177/Johnson & Johnson announced that its Tecnis Odyssey IOL has now been implanted in 100,000 eyes since its 2024 launch. The company will highlight this milestone alongside new data presentations and technology showcases
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&